Genmab — Director's Dealing 2025

Dec 18, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Merus N.V. (MRUS)
CIK: 0001651311
Period of Report: 2025-12-12

Reporting Person: GENMAB A/S (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, nominal value EUR 0.09 per share	71463077	Indirect

Footnotes

F1: On September 29, 2025, Genmab A/S ("Parent"), Genmab Holding II B.V., a wholly owned subsidiary of Parent ("Purchaser"), and the Issuer entered into a transaction agreement (the "Transaction Agreement"). Pursuant to the terms of the Transaction Agreement, Purchaser commenced a tender offer for all the issued and outstanding common shares, nominal value EUR 0.09 per share (the "Common Shares") of the Issuer (the "Offer"), and, on December 12, 2025, following the expiration of the initial offering period of the Offer (the "Expiration Time"), Purchaser accepted 71,463,077 Common Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Expiration Time, representing approximately 94.2% of the Issuer's outstanding Common Shares, in exchange for a cash payment equal to $97.00 per Common Share, without interest and less applicable withholding taxes. Parent, as the parent entity of Purchaser, beneficially owns the Common Shares held directly by Purchaser.